Equities

Diagnos Inc

Diagnos Inc

Actions
TechnologyTechnology
  • Price (CAD)0.31
  • Today's Change0.00 / 0.00%
  • Shares traded115.00k
  • 1 Year change-30.34%
  • Beta-0.5318
Data delayed at least 15 minutes, as of Nov 08 2024 20:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in CAD

The one analyst offering a 12 month price target expects Diagnos Inc share price to rise to 1.50 in the next year from the last price of 0.31.
High383.9%1.50
Med383.9%1.50
Low383.9%1.50

Earnings history & estimates in CAD

On Aug 21, 2024, Diagnos Inc reported 1st quarter 2025 losses of -0.01 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 1st quarter results by 9.09%.
The next earnings announcement is expected on Nov 26, 2024.
Average growth rate+2.27%
Diagnos Inc reported annual 2024 losses of -0.04 per share on Jul 17, 2024.
Average growth rate-11.11%
More ▼

Revenue history & estimates in CAD

DIAGNOS Inc. had 1st quarter 2025 revenues of 37.00k. This missed the 68.00k estimate of the one analyst following the company. This was 13.95% below the prior year's 1st quarter results.
Average growth rate+0.80%
DIAGNOS Inc. had revenues for the full year 2024 of 170.00k. This was 65.02% below the prior year's results.
Average growth rate+3.37%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.